Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Pres. Restrictions Dosage
391 Continuous Ambulatory Peritoneal Dialysis Solution containing 1.5% Dextrose B05DB00908H2501XX B For chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centre Dose depending on clinical cases
392 Continuous Ambulatory Peritoneal Dialysis Solution containing 2.5% Dextrose B05DB00908H2502XX B For chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centre Dose depending on clinical cases
393 Continuous Ambulatory Peritoneal Dialysis Solution containing 4.25% Dextrose B05DB00908H2503XX B For chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centre Dose depending on clinical cases
394 Copper 250 mm2 Intrauterine Device G02BA02000M9001XX B Intrauterine contraception One unit intrauterine device to be inserted into the uterine cavity on the last day of the menstrual flow or in the first days afterwards. It is advised that the Multiload Cu 250 devices are replaced every 3 years
395 Copper 375 mm2 Intrauterine Device G02BA02000M9002XX B Contraception One unit intrauterine device to be inserted into the uterine cavity on the last day of the menstrual flow or in the first days afterwards. It is advised that the Multiload Cu 375 devices are replaced every 5 years
396 Copper Sulphate Crystal D08A000183F9901XX C Wounds The tip of the crystal should be moistened by dipping in water and applied carefully to the lesion
397 Corifollitropin Alfa 100mcg/0.5ml solution for injection G03GA09000P5001XX A* Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in woman participating in an Assisted Reproductive Technology (ART) program Restriction: As second line treatment alternative to other recombinant FSH Women with Body Weight ≤60 kg: A single dose of 100 mcg should be administered. Women with Body Weight >60 kg: A single dose of 150 mcg should be administered. Details : Refer to Product Information
398 Corifollitropin Alfa 150mcg/0.5ml solution for injection G03GA09000P5002XX A* Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in woman participating in an Assisted Reproductive Technology (ART) program Restriction: As second line treatment alternative to other recombinant FSH Women with Body Weight ≤60 kg: A single dose of 100 mcg should be administered. Women with Body Weight >60 kg: A single dose of 150 mcg should be administered. Details : Refer to Product Information
399 Cortisone Acetate 5 mg Tablet H02AB10122T1002XX B For salt losing congenital adrenal hyperplasia in newborn and paediatric patients 20-30 mg/m2 daily. Doses may be divided with two-thirds in the morning and one-third late in the afternoon
400 Crotamiton 10 % Cream P03A000000G1001XX B i) Pruritus ii) Scabies iii) Insect bite reactions i) and iii) Massage into affected area until the medication is completely absorbed. Repeat as needed. Apply 2 or 3 times daily ii) Apply to the whole body from below the chin. 2nd application is applied 24 hr later. May need to use once daily for up to 5 days.
401 Cyanocobalamin 0.1 mg Injection B03BA01000P3001XX B i) Prophylaxis of anaemia ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption i) Prophylaxis of anaemia: 250-1000 mcg IM every month ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption: Initial 100 mcg daily for 5-10 days followed by 100-200 mcg monthly until complete remission is achieved. Maintenance: up to 1000 mcg monthly. CHILD 30-50 mcg daily for 2 or more weeks (to a total dose of 1-5mg). Maintenance: 100 mcg monthly to sustain remission OR AS PRESCRIBED.
402 Cyanocobalamin 1 mg Injection B03BA01000P3002XX B i) Prophylaxis of anaemia associated with Vitamin B12 deficiency ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption i) Prophylaxis of anaemia: 250-1000 mcg IM every month ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption: Initial 100 mcg daily for 5-10 days followed by 100-200 mcg monthly until complete remission is achieved. Maintenance: up to 1000 mcg monthly. CHILD 30-50 mcg daily for 2 or more weeks (to a total dose of 1-5mg). OR AS PRESCRIBED.
403 Cyanocobalamin 50 mcg Tablet B03BA01000T1002XX B Vitamin B12 deficiency of dietary origin ADULT 50-150 mcg daily. CHILD 50-105 mcg daily in 1-3 divided doses
404 Cyclopentolate 0.2% with Phenylephrine 1% Eye Drops S01GA55990D2001XX A Dilating agent for premature babies 1 drop every 5 - 10 minutes; not exceeding three times to produce rapid mydriasis. Observe infants closely for at least 30 minutes
405 Cyclopentolate 1% Eye Drops S01FA04000D2002XX A Mydriasis and cycloplegia ADULT : 1 drop of solution in eye(s); may repeat after 5-10 minutes if needed. CHILD : 1 drop of solution in eye(s); may repeat after 5-10 minutes if needed. Pre-treatment on the day prior to examination is usually not necessary. If desirable, 1 or 2 drops may be instilled the evening prior to examination.
406 Cyclophosphamide 1 g Injection L01AA01000P4002XX A i) Solid tumours; ii) Leukaemia, non-Hodgkin's lymphoma, multiple myeloma; iii) Severe lupus nephritis (Class III and IV); iv) Other systemic vasculitis; v) Systemic lupus erythematosus, rheumatoid arthritis, polyarteritis nodosa, wegener granulomatosis; vi) Pemphigus vulgaris. i)& ii) ADULT: 600 - 750 mg/m2 IV once every 3 weeks as part of combination regime. CHILD: Dose variable depending on disease and protocol. Range 600 mg/m2 to 2 g/m2 infusion over 1 hour to 6 hours (lower doses can be given as bolus). Care with pre and post-hydration. Mesna to be given with doses more than 1 g/m2. Higher doses are used in haematopoetic stem cell transplant-refer to specific protocols iii) 750 mg/m2 BSA monthly for 18 months iv) 750 mg/m2 BSA monthly for 6 months. Dose can be adjusted up to 1,000 mg/m2 BSA to achieve adequate leucocyte suppression v) 500 - 1000 mg intravenously (Regime varies according to indication). Starting dose may be given fortnightly then at monthly intervals followed by 3 monthly intervals; vi) 500 mg infusion on the 2nd day of the dexamethasone-cyclophosphamide pulsed regime, the cycle is repeated every 4 weeks up to 6 cycles or till remission followed by oral cyclophosphamide
407 Cyclophosphamide 200 mg Injection L01AA01000P4001XX A i) Solid tumours; ii) Leukaemia, non-Hodgkin's lymphoma, multiple myeloma; iii) Severe lupus nephritis (Class III and IV); iv) Other systemic vasculitis; v) Systemic lupus erythematosus, rheumatoid arthritis, polyarteritis nodosa, wegener granulomatosis; vi) Pemphigus vulgaris. i)& ii) ADULT: 600 - 750 mg/m2 IV once every 3 weeks as part of combination regime. CHILD: Dose variable depending on disease and protocol. Range 600 mg/m2 to 2 g/m2 infusion over 1 hour to 6 hours (lower doses can be given as bolus). Care with pre and post-hydration. Mesna to be given with doses more than 1 g/m2. Higher doses are used in haematopoetic stem cell transplant-refer to specific protocols iii) 750 mg/m2 BSA monthly for 18 months iv) 750 mg/m2 BSA monthly for 6 months. Dose can be adjusted up to 1,000 mg/m2 BSA to achieve adequate leucocyte suppression v) 500 - 1000 mg intravenously (Regime varies according to indication). Starting dose may be given fortnightly then at monthly intervals followed by 3 monthly intervals; vi) 500 mg infusion on the 2nd day of the dexamethasone-cyclophosphamide pulsed regime, the cycle is repeated every 4 weeks up to 6 cycles or till remission followed by oral cyclophosphamide
408 Cyclophosphamide 50 mg Tablet L01AA01000T1001XX A i) Solid tumours, leukaemia, lymphoma, autoimmune disorders, autoimmune bullous diseases, connective tissue disease, pyoderma gangrenosum ii) For severe lupus nephritis (Class III & IV), systemic vasculitis and steroid resistant/dependent nephrotic syndrome iii) Systemic lupus erythematosus (SLE), rheumatoid arthritis, polyarteritis nodosa, wegener granulomatosis i) ADULT: 50 - 100 mg/day. Monitor full blood count (FBC), liver function, urine microscopy and renal function. CHILD, up to 1 year: 10 - 20 mg daily, 1 - 5 years: 30 - 50 mg daily, 6 - 12 years: 50 - 100 mg daily ii) 2 mg/kg/day for 3 - 4 months iii) 1 - 1.5 mg/kg/day orally in divided doses
409 Cycloserine 250 mg Capsule J04AB01000C1001XX A* Multi-Drug Resistance Tuberculosis treatment failure. (For respiratory physicians) ADULT: Initial: 250 mg every 12 hours for 14 days, then administer 0.5 - 1 g daily in 2 divided doses for 18 - 24 months (maximum daily dose: 1 g). CHILD: 2-12 yr: 5 mg/kg bid; 12-18 yr: 250 mg bid for 2 wk then adjusted to a max dose of 1 g daily
410 Cyproterone Acetate 2 mg & Ethinyloestradiol 0.035 mg Tablet G03HB01954T1001XX A* Androgen dependent diseases in women 1 tablet daily for 21 days on the first day of the cycle, followed by 7 tab free days. Starting on day 2 to 5 is allowed, but during the first cycle a barrier method is recommended for the first 7days of tablet taking.
411 Cyproterone Acetate 50 mg Tablet G03HA01122T1001XX A* Carcinoma of prostate i) After orchidectomy, 100 mg once daily or twice daily ii) If used together with LHRH agonists, the initial dose is 100 mg twice daily for 5 to 7 days before the start of LHRH agonist, then 100 mg twice daily for 3 to 4 weeks together with the LHRH agonist
412 Cytarabine 100 mg/mL Injection L01BC01000P4002XX A i) Central nervous system lymphoma ii) Meningeal leukemia iii) Non Hodgkin's Lymphoma iv) High dose cytarabine as conditioning to cytoreduce the disease before stem cell transplant for relapsed or refractory leukemia v) As salvage for acute lymphocytic leukemia vi) As salvage for acute myeloid leukemia vii) As palliative chemotherapy in elderly acute myeloid leukemia/ myelodysplastic syndrome Standard doses 100 - 200 mg/m2 daily over 5 - 10 days. Higher doses for intensification/consolidation: 1000 - 3000 mg/m2 daily over 3 - 5 days depending on specific protocols. CHILD: Dose variable depending on disease and protocol. Range from 100 mg/m2 to 3 g/m2 twice daily. May be given as SC, IV bolus or infusion. Intrathecal dose: Less than 1 year: 15 mg, 1 - 2 years: 20 mg, 2 - 3 years: 25 mg, more than 3 years: 30 mg. (ENSURE THAT PREPARATION IS SUITABLE FOR INTRATHECAL USE)
413 D-Penicillamine 0.25 g Capsule M01CC01000C1001XX A i) Treatment of severe lead poisoning, it is used as adjunctive treatment following initial treatment with another chelating agent. May also be used as sole therapy in the treatment of asymptomatic patients with moderately elevated blood concentrations ii) Wilson's Disease: to aid in elimination of copper ions i) Heavy metal poisoning: 900mg-1800mg daily. Duration of treatment is dictated by the urinary heavy metal excretion. Simultaneous oral vitamin B6 replacement with at least 40mg daily is essential ii) Wilson's disease: 0.25g - 1.5g daily on an incremental basis. Maximal daily dose: 2g. Maintenance dose: 0.75g - 1g daily
414 Dabigatran Etexilate 110 mg Capsule B01AE07999C1002XX A* i) Prevention of venous thromboembolic events in patients who have undergone total knee replacement or total hip replacement surgery. ii) Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). iii) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults. i) Following total knee replacement: Initially ADULT 110mg (ELDERLY, 75 mg) within 1- 4 hours after surgery, then 220 mg (ELDERLY, 150 mg) once daily thereafter for 6-10 days Following total hip replacement: Initially ADULT 110 mg (ELDERLY, 75 mg) within 1- 4 hours after surgery, then 220 mg (ELDERLY, 150 mg) once daily thereafter for 28-35 days ii) Recommended daily dose is 300mg taken orally as 150mg hard capsule twice daily. Therapy should be continued lifelong. iii) Recommended daily dose is 300mg taken as one 150mg capsule BD following treatment with a parenteral anticoagulant for at least 5 days. The duration of therapy should be individualized after careful assessment of the treatment benefit against the risk for bleeding. ii) & iii) For the following groups, the recommended daily dose is 220 mg taken as one 110mg capsule twice daily: - Patients aged 80 years or above -Patients who receive concomitant verapamil Special patient population for renal impairment : Renal function should be assessed by calculating the creatinine clearance (CrCl) prior to initiation of treatment with Dabigatran to exclude patients for treatment with severe renal impairment (i.e. CrCl < 30 ml/min).
415 Dabigatran Etexilate 75 mg Capsule B01AE07999C1001XX A* Prevention of venous thromboembolic events in patients who have undergone total knee replacement or total hip replacement surgery Following total knee replacement: Initially ADULT 110 mg (ELDERLY, 75 mg) within 1- 4 hours after surgery, then 220 mg (ELDERLY, 150 mg) once daily thereafter for 6-10 days Following total hip replacement: Initially ADULT 110 mg (ELDERLY, 75 mg) within 1- 4 hours after surgery, then 220 mg (ELDERLY, 150 mg) once daily thereafter for 28-35 days
416 Dabigatran Etexilate150 mg Capsule B01AE07999C1003XX A* i) Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) ii) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults. i) Recommended daily dose is 300mg taken orally as 150mg hard capsule twice daily. Therapy should be continued lifelong. ii) Recommended daily dose is 300mg taken as one 150mg capsule BD following treatment with a parenteral anticoagulant for at least 5 days. The duration of therapy should be individualized after careful assessment of the treatment benefit against the risk for bleeding. For the following groups, the recommended daily dose is 220 mg taken as one 110mg capsule twice daily: - Patients aged 80 years or above -Patients who receive concomitant verapamil Special patient population for renal impairment : Renal function should be assessed by calculating the creatinine clearance (CrCl) prior to initiation of treatment with Dabigatran to exclude patients for treatment with severe renal impairment (i.e. CrCl < 30 ml/min).
417 Dacarbazine 100 mg Injection L01AX04000P4001XX A* i) Malignant melanoma, sarcomas, neuroblastomas and other childhood solid tumours ii) Hodgkin's Disease i) 250 mg/m2 for 5 days, may be repeated every 3 weeks ii) 375 mg/m2 IV every 2 weeks
418 Daclatasvir 30mg tablet J05AP07-110-T32-02-XXX A/KK To be used in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults. 60 mg once daily, to be taken orally with or without meals. Dose recommendation when taking concomitant medicines: i. Strong inhibitors of cytochrome P450 enzyme 3A4 (CYP3A4): Reduce dose to 30 mg once daily when co-administered with strong inhibitors of CYP3A4. ii. Moderate inducers of CYP3A4: Increase dose to 90 mg once daily when co-administered with moderate inducers of CYP3A4. Daclatasvir must be administered in combination with other medicinal products for the treatment of hepatitis C infection. Dose modification of daclatasvir to manage adverse reactions is not recommended.
419 Daclatasvir 60mg tablet J05AP07-110-T32-01-XXX A/KK To be used in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults. 60 mg once daily, to be taken orally with or without meals. Dose recommendation when taking concomitant medicines: i. Strong inhibitors of cytochrome P450 enzyme 3A4 (CYP3A4): Reduce dose to 30 mg once daily when co-administered with strong inhibitors of CYP3A4. ii. Moderate inducers of CYP3A4: Increase dose to 90 mg once daily when co-administered with moderate inducers of CYP3A4. Daclatasvir must be administered in combination with other medicinal products for the treatment of hepatitis C infection. Dose modification of daclatasvir to manage adverse reactions is not recommended.
420 Danazol 100 mg Capsule G03XA01000C1001XX A/KK i)Endometriosis and gynaecomastia ii)Menorrhagia iii)Prophylaxis of hereditary angioedema i)200 - 800 mg daily for max of 9 months ii)200 mg daily for 12 weeks ii)400 mg daily. Reduce to 200 mg daily after 2 months attack free period

Halaman-halaman